Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 and Ivonescimab in Advanced Solid Tumors
NCT07208773Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Oct 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of YL201 in solid tumor, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by MediLink Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
YL201
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07208773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208773.